ArticleBMC genomics2011
False negative rates in Drosophila cell-based RNAi screens: a case study.
Article in BMC genomics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Rapid and robust validation of pooled CRISPR knockout screens using CelFi.Scientific reports · 2025Article
- An image-based RNAi screen identifies the EGFR signaling pathway as a regulator of Imp RNP granules.Journal of cell science · 2024Article
- The Current Situation and Development Prospect of Whole-Genome Screening.International journal of molecular sciences · 2024Review
- Dual Leucine Zipper Kinase Regulates Dscam Expression through a Noncanonical Function of the Cytoplasmic Poly(A)-Binding Protein.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2022Article
- Genome-wide RNAi screen in Drosophila reveals Enok as a novel trithorax group regulator.Epigenetics & chromatin · 2019Article
- Tissue-specific (ts)CRISPR as an efficient strategy for in vivo screening in Drosophila.Nature communications · 2019Article
- Genome-scale CRISPR knockout screen identifiesCommunications biology · 2019Article
- CRISPR Technology for Breast Cancer: Diagnostics, Modeling, and Therapy.Advanced biosystems · 2018Article
- An efficient and multiple target transgenic RNAi technique with low toxicity in Drosophila.Nature communications · 2018Article
- New tools for old drugs: Functional genetic screens to optimize current chemotherapy.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2018Review
- Multiplex shRNA Screening of Germ Cell Development by in Vivo Transfection of Mouse Testis.G3 (Bethesda, Md.) · 2017Article
- Genetic dissection of intraspecific variation in a male-specific sexual trait in Drosophila melanogaster.Heredity · 2016Article
- Multiplexed barcoded CRISPR-Cas9 screening enabled by CombiGEM.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Functional Genomic Strategies for Elucidating Human-Virus Interactions: Will CRISPR Knockout RNAi and Haploid Cells?Advances in virus research · 2016Review
- Reagent and Data Resources for Investigation of RNA Binding Protein Functions in Drosophila melanogaster Cultured Cells.G3 (Bethesda, Md.) · 2015Article
- RNA-guided CRISPR-Cas technologies for genome-scale investigation of disease processes.Journal of hematology & oncology · 2015Review
- Mitochondrial targets for pharmacological intervention in human disease.Journal of proteome research · 2015Review
- Integration of biological data by kernels on graph nodes allows prediction of new genes involved in mitotic chromosome condensation.Molecular biology of the cell · 2014Article
- RNAi screening in Drosophila cells and in vivo.Methods (San Diego, Calif.) · 2014Review
- Genetic screens in human cells using the CRISPR-Cas9 system.Science (New York, N.Y.) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHigh-throughput screening using RNAi is a powerful gene discovery method but is often complicated by false positive and false negative results. Whereas false positive results associated with RNAi reagents has been a matter of extensive study, the issue of false negatives has received less attention.
resultsWe performed a meta-analysis of several genome-wide, cell-based Drosophila RNAi screens, together with a more focused RNAi screen, and conclude that the rate of false negative results is at least 8%. Further, we demonstrate how knowledge of the cell transcriptome can be used to resolve ambiguous results and how the number of false negative results can be reduced by using multiple, independently-tested RNAi reagents per gene.
conclusionsRNAi reagents that target the same gene do not always yield consistent results due to false positives and weak or ineffective reagents. False positive results can be partially minimized by filtering with transcriptome data. RNAi libraries with multiple reagents per gene also reduce false positive and false negative outcomes when inconsistent results are disambiguated carefully.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.